Combination drug therapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two new drugs for advanced colorectal cancer. One drug targets a protein on cancer cells (EGFR) and delivers a chemotherapy-like agent directly to the tumor, while the other boosts the immune system to fight cancer. Participation may offer a new option if standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your colorectal cancer has returned or spread, and your tumor tests positive for a protein called EGFR.
- You have already received at least two standard treatments for your cancer.
- You are able to care for yourself (daily activities) and your expected survival is at least 12 weeks.
- Your blood counts and liver/kidney function are within acceptable levels.
- You are not pregnant and agree to use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications for people with advanced colorectal cancer who cannot tolerate stronger chemotherapy. The goal is to see if this gentler approach slows tumor growth and improves quality of life.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.